These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29316137)

  • 1. Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2018 May; 20(5):1089-1095. PubMed ID: 29316137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
    Fisher M
    Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
    J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 11. Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.
    Kosiborod M
    J Diabetes Complications; 2017 Feb; 31(2):517-519. PubMed ID: 27839923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure.
    Packer M
    Diabet Med; 2018 Jun; 35(6):707-713. PubMed ID: 29532519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
    White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
    Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].
    Ambrosio G; De Ferrari GM; Federici M; Filardi PP
    G Ital Cardiol (Rome); 2017 Jun; 18(6):485-495. PubMed ID: 28631762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the waist-to-height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE-ON study.
    Rådholm K; Chalmers J; Ohkuma T; Peters S; Poulter N; Hamet P; Harrap S; Woodward M
    Diabetes Obes Metab; 2018 Aug; 20(8):1903-1910. PubMed ID: 29603537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
    Khunti K; Kosiborod M; Ray KK
    Diabetes Obes Metab; 2018 Jun; 20(6):1337-1341. PubMed ID: 29405543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Metabolic control or reduction of vascular risk with current treatments. What is the priority?].
    Alonso Fernández M
    Semergen; 2018 Jun; 44 Suppl 1():26-32. PubMed ID: 30322470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.